CE‐MS‐based proteomics in biomarker discovery and clinical application

Authors:
Publisher website
Google Scholar
Abstract
CE‐MS is applied in clinical proteomics for both the identification of biomarkers of disease and assessment of biomarkers in clinical diagnosis. The analysis is reproducible, fast, and requires only small sample volumes. However, successful CE‐MS analysis depends on several critical steps that can be consolidated as follows: (i) proper sample preparation and fractionation, (ii) application of suitable capillary coating and appropriate CE‐MS interfaces, to ensure the reproducibility and stability of the analysis, and (iii) an optimized clinical and statistical study design to increase the chances for obtaining clinically relevant results. In this review, we cover all these aspects, and present several examples of the application of CE‐MS in clinical proteomics.
Funding Information
  • Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction (FP-HEALTH-INNOVATION-2013-2, GA 601933)
  • Clinical and system-omics for the identification of the Molecular Determinants of established Chronic Kidney Disease (PEOPLE-ITN-GA-2013-608332)
  • Molecular Medicine for Bladder Cancer (PITN-GA-2012-317450-BCMolMed)
  • Systems Biology to Identify Molecular Targets for Vascular Disease Treatment (HEALTH-2013 603288)

This publication has 90 references indexed in Scilit: